65,437 trials
Diabetes · Glycemic Control
Primary: The Long Term Effect of Intensive Glycemic Control in Type 2 Diabetes on Major Cardiovascular Complication. — 336; 325 number of events — p=0.24
Cataract
Primary: Anterior Chamber Inflammation — .913; .783 grade of anterior chamber cells
Coronary Artery Disease
Primary: Attendance at Cardiac Rehabilitation Exercise Sessions — 36; 19 Participants
Head and Neck Squamous Cell Carcinoma
Primary: Change in Immune Response After Tadalafil Administration — 1.13; 1.59; 1.14; 4.74 fold change
Choriocarcinoma
Primary: Progression Free Survival of Two Patients With Metastatic and Refractory Choriocarcinoma — 18 Months
Hip Arthroscopy · Nerve Block
Primary: Pain Score Change — 3; 1.72 change in score on a scale
Eales' Disease
Primary: Change in OCT Thickness. — 269; 262 um
Acute Myeloid Leukemia
Primary: Number of Participants With Adverse Events (Safety Profile) — 6; 13; 2; 11 Participants
Epilepsy, Partial
Primary: Partial (Type I) Seizure Frequency Per Week by Analysis Visit — 1.68; 2.19; 1.69; 2.00 Number of Seizures (Type I) per week
Sinusitis
Primary: Proportion of Children With Clinical Relapse on Day 10 (Short Course) vs Day 20 (Long Course) — 13; 8; 9; 10 Participants
Preterm Infants
Primary: Number of Participants Who Required Intubation — 26; 15 Participants
Stage III Ovarian Cancer
Primary: Satisfaction With Decision — 85.3; 86.9; 85.8; 91.5 transformed scale score — p=0.582
Coronary Artery Disease
Primary: Feasibility and Usability of activPAL3 and VTAP Devices — 14; 19 Participants
Abortion
Primary: Number of Participants Who Use Patch After Abortion, by Study Arm — 36; 42 Participants
Anesthesia
Primary: Dose of Propofol Required to Prevent Movement (Response) to Insertion of Endoscope Into the Patient's Esophagus — 6.1; 4.5; 4.7; 1.1 mg/kg